Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
- Authors
- Tan, Jack Wei Chieh; Sim, David; Ako, Junya; Almahmeed, Wael; Cooper, Mark E.; Dalal, Jamshed J.; Deerochanawong, Chaicharn; Huang, David Wei Chun; Johar, Sofian; Kaul, Upendra; Kim, Sin Gon; Koh, Natalie; Kong, Alice Pik-Shan; Krittayaphong, Rungroj; Kwok, Bernard; Matawaran, Bien J.; Quang Ngoc Nguyen; Ong, Loke Meng; Park, Jin Joo; Peng, Yongde; Quek, David K. L.; Suastika, Ketut; Sukor, Norlela; Teo, Boon Wee; Teoh, Chee Kiang; Zhang, Jian; Reyes, Eugenio B.; Goh, Su Yen
- Issue Date
- 2021
- Publisher
- RADCLIFFE CARDIOLOGY
- Keywords
- Type 2 diabetes; cardiovascular; sodium-glucose cotransporter 2 inhibitor; glucagon-like protein 1 receptor agonist; consensus; Asia Pacific; prediabetes
- Citation
- EUROPEAN CARDIOLOGY REVIEW, v.16
- Indexed
- SCOPUS
- Journal Title
- EUROPEAN CARDIOLOGY REVIEW
- Volume
- 16
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/130205
- DOI
- 10.15420/ecr.2020.52
- ISSN
- 1758-3756
- Abstract
- The Asian Pacific Society of Cardiology convened a consensus statement panel for optimising cardiovascular (CV) outcomes in type 2 diabetes, and reviewed the current literature. Relevant articles were appraised using the Grading of Recommendations, Assessment, Development and Evaluation system, and consensus statements were developed in two meetings and were confirmed through online voting. The consensus statements indicated that lifestyle interventions must be emphasised for patients with prediabetes, and optimal glucose control should be encouraged when possible. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recommended for patients with chronic kidney disease with adequate renal function, and for patients with heart failure with reduced ejection fraction. In addition to SGLT2i, glucagon-like peptide-1 receptor agonists are recommended for patients at high risk of CV events. A blood pressure target below 140/90 mmHg is generally recommended for patients with type 2 diabetes. Antiplatelet therapy is recommended for secondary prevention in patients with atherosclerotic CV disease.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.